Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

10 results about "Adamantane derivatives" patented technology

Adamantane derivative as well as synthesis method and application thereof

The invention belongs to the technical field of drug synthesis, and particularly relates to an adamantane derivative as well as a synthesis method and application thereof. The adamantane derivative comprises an intermediate structural formula I, an intermediate structural formula II and an intermediate structural formula III, and the structural general formula is as follows: Linker is substituted or unsubstituted C6-C10 aroyl, R1 is hydrogen or C1-C6 alkyl, R2 is hydrogen, C1-C6 alkyl or a nitrogen-containing or nitrogen-free structural fragment, or the integral structure of R1R2 is N-substituted heterocyclic pentyl or heterocyclic cyclohexyl. According to the adamantane derivative provided by the invention, an adamantane structure is combined with part of groups of OAB-14, and a parent nucleus structure is changed, so that the drug activity is improved. The invention also provides a synthesis method of the compound, the obtained compound is screened through cell viability research, and the compound has a potential synergistic effect in the aspects of preventing influenza and treating Alzheimer's disease.
Owner:SHANDONG XINHUA PHARMA CO LTD

Zanamivir and derivative thereof-adamantane derivative covalent conjugate and anti-influenza virus application thereof

The invention provides zanamivir and derivatives thereof, namely adamantane derivative covalent conjugates and application of the zanamivir and the derivatives thereof in resisting influenza viruses. The structure of the zanamivir and the derivative thereof-adamantane derivative covalent conjugate is as shown in formula I in the specification. The invention also provides a method for preparing the zanamivir and the derivative of the zanamivir-adamantane derivative covalent conjugate and a pharmaceutical composition containing the zanamivir and the derivative of the zanamivir-adamantane derivative covalent conjugate. The covalent conjugate provided by the invention not only can improve the pharmacokinetic property of zanamivir, but also has the activity of an M2 ion channel / NA enzyme for inhibiting double targets, can efficiently inhibit influenza viruses, and has relatively high safety.
Owner:PEKING UNIV

Anti-cancer activity of adamantane derivatives

Provided herein are methods for treating cancer comprising administering to a subject in need thereof an adamantane derivative, or a pharmaceutically acceptable salt thereof, such as rimantadine or amantadine. In some embodiments, the adamantane derivative is PEGylated.
Owner:RGT UNIV OF CALIFORNIA

Non-chemically amplified multi-phenyl substituted adamantane derivative monomolecular resin photoresist, preparation method and application thereof

The application discloses a polyphenyl-substituted adamantane derivative monomolecular resin represented by formula IA and a preparation method and application thereof. The polyphenyl-substituted adamantane derivative monomolecular resin has good solubility in various polar solvents, is suitable for being made into a film, has a high decomposition temperature, and can well meet the requirements of a photoetching process.
Owner:TECHNICAL INST OF PHYSICS & CHEMISTRY - CHINESE ACAD OF SCI

Injectable biocompatible hydrogel based on dynamic supramolecular assembly

The invention relates to the technical field of biomedical materials, and discloses an injectable biocompatible hydrogel based on dynamic supramolecular assembly, and the hydrogel comprises the following components by weight: 3.0-5.0% of zinc oxide nanocrystalline regenerated cellulose; 3.0%-5.0% of chondroitin sulfate; 1.5% to 2.5% of recombinant human source collagen; 1%-2% of beta-sodium glycerophosphate; 0.7%-1% of a cyclodextrin polymer; 0.4%-0.7% of an adamantane derivative; 0.3% to 0.5% of PEI-DNA nano particles; 0.1% to 0.3% of calcium citrate; 0.1% to 0.2% of sodium alginate microspheres; 0.15%-0.2% of a pH buffer agent; the preparation method comprises the following steps: taking collagen as a raw material, taking sterile deionized water and normal saline as residual components, and adjusting the components through subject-object supramolecular interaction, ionic crosslinking, collagen thermosensitive assembly and a step-by-step mixing process and structure, so that the prepared hydrogel has the advantages of dynamic reversible crosslinking, shear thinning and self-healing synergy, high biocompatibility and controllable degradation rate.
Owner:YANGZHOU POLYTECHNIC INST

A low-acid-value modified epoxy acrylic resin solder resist ink and its preparation method

ActiveCN120682664BInksEpoxyPolymer science
This invention provides a low-acid-value modified epoxy acrylate resin solder resist ink and its preparation method, comprising composition A and composition B. Composition A comprises the following components: acrylic resin, low-acid-value modified epoxy acrylate resin, modified boron nitride, acrylate monomer, photoinitiator, additives, and solvent. Composition B comprises the following components in parts by weight: alicyclic epoxy resin, additives, and solvent. The modified boron nitride is adamantane derivative-modified hexagonal boron nitride. This invention's low-acid-value modified epoxy acrylate resin solder resist ink is a compound of multiple components, including low-acid-value modified epoxy acrylate resin and modified boron nitride, effectively improving the ink's stability, dispersibility, coating strength, adhesion, and other properties. It solves the shortcomings and problems of existing technologies and is of great significance to the development of solder resist inks.
Owner:HESHAN S M MATERIALS CORP

adamantane derivatives, their synthesis methods and applications

This invention belongs to the technical field of drug synthesis, specifically relating to adamantane derivatives, their synthetic methods, and applications. The adamantane derivatives described in this invention include intermediate structural formulas I, II, and III, as well as structures with the following general formula: Linker is a substituted or unsubstituted C6-C10 aryl group; R1 is hydrogen or a C1-C6 alkyl group; R2 is hydrogen, a C1-C6 alkyl group, or a nitrogen-containing or nitrogen-free structural fragment; or the overall structure of R1R2 is an N-substituted heterocyclopentyl or heterocyclohexyl group. The adamantane derivatives provided by this invention combine the adamantane structure with a portion of the OAB-14 group, altering the core structure and thus improving drug activity. This invention also provides a synthetic method for these derivatives. Through cellular activity studies, the resulting compounds are screened, demonstrating potential synergistic effects in the prevention of influenza and the treatment of Alzheimer's disease.
Owner:SHANDONG XINHUA PHARMA CO LTD

BCB alkenyl adamantane derivative, preparation method thereof and hydride

The invention relates to the technical field of low-dielectric materials, and particularly discloses a BCB alkenyl adamantane derivative, a preparation method thereof and hydride, and the derivative is specifically shown as follows: at least one BCB alkenyl is contained in substituent groups at 1, 3, 5 and 7 positions of adamantane. According to the present invention, with the strategy of introducing the BCB alkenyl group to the adamantane substituent group, the obtained BCB alkenyl adamantane derivative has characteristics of good thermal property and low dielectric property; meanwhile, the number of substituent groups and the number of BCB alkenyl groups on each substituent group are set as parameters capable of being flexibly adjusted, so that the performance of the derivative can be accurately optimized according to actual requirements. Compared with the prior art, pertinent regulation and control of dielectric constants of existing derivatives can be achieved by adjusting the number of substituent groups, the number of BCB alkenyl groups and other groups on the substituent groups, then directional control over the properties of the derivatives is achieved, and the problem that in the prior art, low-dielectric materials in the fields of high-performance PCBs, electronic packaging and the like are met is solved.
Owner:WUHAN DESYTEK ENVIRONMENTAL PROTECTION NEW MATERIAL CO LTD

Adamantane derivatives as inhibitors of focal adhesion kinase

The present invention provides novel adamantane derivatives as inhibitors of a focal adhesion kinase, pharmaceutically acceptable salts thereof, stereoisomers thereof, hydrates or solvates thereof, and a pharmaceutical composition comprising same.
Owner:BAMICHEM +2

Pyrogallol derivative as well as preparation method and application thereof

The invention discloses a pyrogallol derivative and a preparation method and application thereof, firstly provides pyrogallol derivatives shown as general formulas (A), (B) and (C) or pharmaceutically acceptable salts thereof, and further provides a preparation method of the pyrogallol derivative. Finally, the invention also discloses application of the pyrogallol derivative in preparation of a medicine for preventing or treating coronavirus infection. The pyrogallol derivative can inhibit the activity of SARS-CoV-2 Mpro, wherein R is selected from an adamantane derivative or a bicyclo [1.1. 1] pentane fragment.
Owner:YUNNAN UNIVERSITY OF CHINESE MEDICINE